Effects of suloctidil on platelet survival time following cardiac valve replacement

Thromb Haemost. 1981 Aug 28;46(2):550-3.


Platelet functions and blood clotting parameters were examined in 23 patients with a shortened platelet survival time after cardiac valve replacement. Treatment was given at random: for a first group antivitamin K with suloctidil and for the second group antivitamin K alone. Six weeks of treatment with antivitamin K alone did not induce any significant change in the platelet survival time, platelet retention or platelet factor 4 in plasma. In contrast, the shortened platelet survival time increased significantly after 6 weeks of treatment with suloctidil. Moreover the platelet retention and the amount of platelet factor 4 in plasma were significantly reduced, indicating that normalization of platelet survival is the result of decreased destruction, presumably at the level of the prosthetic surface. The clinical benefits expected from these results remain to be validated by a longer follow up period.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Acenocoumarol / pharmacology
  • Adult
  • Aged
  • Blood Coagulation / drug effects
  • Blood Platelets / drug effects*
  • Cell Survival / drug effects
  • Fibrinogen / analysis
  • Heart Valve Prosthesis*
  • Heart Valves / surgery*
  • Humans
  • Middle Aged
  • Platelet Aggregation / drug effects
  • Platelet Count
  • Platelet Factor 4 / analysis
  • Propanolamines / pharmacology*
  • Suloctidil / pharmacology*


  • Propanolamines
  • Platelet Factor 4
  • Fibrinogen
  • Acenocoumarol
  • Suloctidil